COVID-19 Ring-based Prevention Trial With Lopinavir/Ritonavir

2020-03-31 04:04:35 | BioPortfolio


COVID-19 has rapidly evolved into a generalized global pandemic. Post-exposure prophylaxis (PEP) against on COVID-19 was identified as an urgent research priority by the WHO, and lopinavir/ritonavir (LPV/r) is a promising candidate for both COVID-19 treatment and PEP, with a good safety profile and global availability. This is a cluster randomized controlled trial (RCT) of oral LPV/r as PEP against COVID-19, that will address the immediate need for preventive interventions, generate key data on COVID-19 transmission, and serve as a research platform for future vaccines and preventive agents.

Study Design


Coronavirus Infections




Sunnybrook Hospital
M4N 3M5


Not yet recruiting


St. Michael's Hospital, Toronto

Results (where available)

View Results


Published on BioPortfolio: 2020-03-31T04:04:35-0400

Clinical Trials [934 Associated Clinical Trials listed on BioPortfolio]

The Efficacy of Lopinavir Plus Ritonavir and Arbidol Against Novel Coronavirus Infection

The study explores the efficacy of lopinavir plus ritonavir and arbidol in treating with novel coronavirus infection. As a result this study would provide evidence for the clinical usage o...

Comparison of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19)

In vitro studies revealed that lopinavir/ritonavir and hydroxychloroquine have antiviral activity against Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, there is no...

Lopinavir/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV Treatment

A combination of lopinavir/ ritonavir, ribavirin and interferon beta-1b will expedite the recovery, suppress the viral load, shorten hospitalisation and reduce mortality in patients with 2...

Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Novel Coronavirus Infection

Base on Arbidol antiviral therapy,the investigators conduct a randomized, open-label trial to evaluate and compare the safety and efficacy of ASC09 /ritonavir and lopinavir/ritonavir in pa...

Study of Lopinavir, Ritonavir, Tenofovir and Emtricitabine in HIV-Infected Antiretroviral Naïve Subjects

The purpose of this study is to compare the safety, tolerability and antiviral activity between once-daily (QD) and twice-daily (BID) dosing of lopinavir/ritonavir and to further character...

PubMed Articles [4045 Associated PubMed Articles listed on BioPortfolio]

Potential antiviral therapeutics for 2019 Novel Coronavirus.

The recent outbreak of respiratory illness in Wuhan, China is caused by a novel coronavirus, named 2019-nCoV, which is genetically close to a bat-derived coronavirus. 2019-nCoV is categorized as beta ...

Inflammatory biomarker levels over 48 weeks with dual vs triple lopinavir/ritonavir-based therapy: Substudy of a randomized trial.

Inflammation has been associated with increased morbidity and mortality in HIV-positive patients. We compared inflammatory biomarkers with dual therapy using lopinavir/ritonavir plus lamivudine (LPV/r...

A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19.

No therapeutics have yet been proven effective for the treatment of severe illness caused by SARS-CoV-2.

Coronavirus infections reported by ProMED, February 2000-January 2020.

Sources describing the global burden of emerging diseases accurately are still limited. We reviewed coronavirus infections reported by ProMED and assessed the reliability of the data retrieved compare...

Integration of computational and experimental approaches to elucidate mechanisms of first-pass lymphatic drug sequestration and long-acting pharmacokinetics of the injectable triple-HIV drug combination TLC-ART 101.

TLC-ART101 is a long-acting triple-HIV drug combination of lopinavir-ritonavir-tenofovir combined in one nano-suspension intended for subcutaneous injection. Following a single TLC-ART 101 administrat...

Medical and Biotech [MESH] Definitions

An HIV protease inhibitor used in a fixed-dose combination with RITONAVIR. It is also an inhibitor of CYTOCHROME P-450 CYP3A.

A species in the genus CORONAVIRUS causing the common cold and possibly nervous system infections in humans. It contains hemagglutinin-esterase.

A species in the genus CORONAVIRUS causing upper and lower RESPIRATORY TRACT INFECTIONS. It shares the receptor used by the SARS VIRUS.

A species in the genus CORONAVIRUS causing the common cold and possibly nervous system infections in humans. It lacks hemagglutinin-esterase.

The type species of BETACORONAVIRUS genus causing gastroenteritis respiratory diseases in mammals. Previously separate species HUMAN CORONAVIRUS OC43; BOVINE CORONAVIRUS; Human enteric coronavirus; Equine coronavirus; and Porcine hemagglutinating encephalomyelitis virus merged into this species on the basis of similar genome nucleotide sequence and genome organization.

More From BioPortfolio on "COVID-19 Ring-based Prevention Trial With Lopinavir/Ritonavir"

Quick Search

Searches Linking to this Trial